Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
This exploratory study investigates the impact of fertility treatments on symptoms of irritable bowel syndrome (IBS) in women. Specifically, the study focuses on two groups:
Background and Rationale PCOS is an endocrine disorder with hormonal and metabolic abnormalities associated with reduced fertility. There are four PCOS phenotypes, of which phenotypes A and B are the "classic" forms. Social freezing is becoming increasingly popular as an option for women without a partner who want to preserve their fertility.
IBS is a common gastrointestinal disorder involving motility disorders and a disturbed gut-brain axis. There is an increased risk of anxiety and depression in IBS patients. Women with PCOS have a twofold increased risk of developing IBS. However, little is known about the effect of hormonal fertility treatments on IBS symptoms.
Objectives
Study design The study is a prospective, interventional exploratory study in which participants complete questionnaires before and after the hormonal stimulation phase.
Data collected
Before treatment:
After treatment:
Questionnaires:
Measuring instruments
Data management
Statistical Analysis
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| PCOS group | Experimental | Women with PCOS fill in questionnaires before ovarian stimulation and after. |
|
| Social freezing group | Experimental | Women who want to freeze their eggs fill in the questionnaires before and after ovarian stimulation. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| questionnaires | Other | Questionnaires: Rome III and IV criteria, GSRS, IBS-SSS, PHQ-9 and GAD-7 |
|
| Measure | Description | Time Frame |
|---|---|---|
| Proportion of participants meeting IBS diagnostic criteria before and after ovarian stimulation | Assessed using Rome III and Rome IV criteria. The number of participants meeting IBS diagnostic criteria will be compared before (at consultation) and after (at oocyte retrieval) ovarian stimulation. | "From start of ovarian stimulation to oocyte retrieval, up to 14 days" |
| Change in IBS symptom severity before and after ovarian stimulation | Assessed using the IBS Severity Scoring System (IBS-SSS), a validated 5-item questionnaire. Total scores range from 0 to 500, with categories: remission (<75), mild (75-175), moderate (175-300), and severe (>300). The total IBS-SSS score will be compared before (at consultation) and after (at oocyte retrieval) ovarian stimulation. | From start of ovarian stimulation to oocyte retrieval, up to 14 days" |
| Measure | Description | Time Frame |
|---|---|---|
| Change in general gastrointestinal symptom severity before and after ovarian stimulation | "Assessed using the Gastrointestinal Symptom Rating Scale (GSRS), a validated 15-item questionnaire scored on a 7-point Likert scale. The total GSRS score will be compared before (at consultation) and after (at oocyte retrieval) ovarian stimulation." | From start of ovarian stimulation to oocyte retrieval, up to 14 days" |
| Measure | Description | Time Frame |
|---|---|---|
| Association between clinical and demographic factors and IBS symptom severity | Subgroup analyses will be performed to assess differences in IBS symptom severity (IBS-SSS and GSRS) based on: type of ovarian stimulation protocol, number of prior fertility treatments, duration of infertility, ethnicity, PCOS subtype, hormonal profile during controlled ovarian stimulation (estradiol, progesterone, LH, FSH), and ultrasound findings |
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Type | Includes Protocol | Includes SAP | Includes ICF | Document Label | Document Date | Document Uploaded Date | Document File Name |
|---|---|---|---|---|---|---|---|
| Prot | Yes | No | No | Study Protocol | Feb 3, 2026 | Mar 23, 2026 |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Change in depression levels before and after ovarian stimulation | Assessed using the Patient Health Questionnaire (PHQ-9), a validated 9-item questionnaire. Total scores range from 0 to 27." | From start of ovarian stimulation to oocyte retrieval, up to 14 days |
| Change in anxiety levels before and after ovarian stimulation | Assessed using the Generalized Anxiety Disorder scale (GAD-7), a validated 7-item questionnaire. Total scores range from 0 to 21." | From start of ovarian stimulation to oocyte retrieval, up to 14 days |
| From start of ovarian stimulation to oocyte retrieval, up to 14 days |
| Prot_000.pdf |
| ICF | No | No | Yes | Informed Consent Form | Nov 18, 2025 | Mar 23, 2026 | ICF_001.pdf |
| ID | Term |
|---|---|
| D011085 | Polycystic Ovary Syndrome |
| ID | Term |
|---|---|
| D010048 | Ovarian Cysts |
| D003560 | Cysts |
| D009369 | Neoplasms |
| D010049 | Ovarian Diseases |
| D000291 | Adnexal Diseases |
| D005831 | Genital Diseases, Female |
| D052776 | Female Urogenital Diseases |
| D005261 | Female Urogenital Diseases and Pregnancy Complications |
| D000091642 | Urogenital Diseases |
| D000091662 | Genital Diseases |
| D006058 | Gonadal Disorders |
| D004700 | Endocrine System Diseases |
Not provided
Not provided
| ID | Term |
|---|---|
| D011795 | Surveys and Questionnaires |
| ID | Term |
|---|---|
| D003625 | Data Collection |
| D004812 | Epidemiologic Methods |
| D008919 | Investigative Techniques |
| D017531 | Health Care Evaluation Mechanisms |
| D011787 | Quality of Health Care |
| D017530 | Health Care Quality, Access, and Evaluation |
| D011634 | Public Health |
| D004778 | Environment and Public Health |
Not provided
Not provided